CAS: 1508-65-2; 4-(Diethylamino)But-2-Yn-1-Yl 2-Cyclohexyl-2-Hydroxy-2-Phenylacetate Hydrochloride

上下游产品

CAS号5633-20-5 奥昔布宁 | CAS号10575-25-4 4-二乙氨基-2-丁炔-1-醇 | CAS号4335-77-7 2-环己基-2-羟基苯乙酸

奥昔布宁置于盐酸体系中,用 甲醇 用作溶剂,化学反应生成盐酸奥昔布宁
参考文献:Substituted Phenylcyclohexylglycolates
标题:Substituted Phenylcyclohexylglycolates
摘要:本文揭示了基于取代苯基环己基甘醇酸酯的 Formula I 的肌氨酸乙酰胆碱受体调节剂,其制备方法,药物组合物及使用方法.

专利信息

专利号:US-6825378-B2
优先权日:2003-03-28
标 题 :Process for the synthesis of enantiomerically pure cyclohexylphenyl glycolic acid
发明人：KUMAR PRADEEP; FERNANDES RODNEY AGUSTINHO; GUPTA PRITI
权利人:COUNCIL SCIENT IND RES
摘要:The present invention provides a process for the synthesis of enantiomerically pure cyclohexylphenyl glycolic acid of formula (1). The present invention more particularly relates to a process using cyclohexylphenyl ketone for the synthesis of enantiomerically pure cyclohexylphenyl glycolic acid of formula (1).

专利号:US-10022366-B2
优先权日:2013-04-23
标 题:Extending and maintaining micropore viability of microneedle treated skin with lipid biosynthesis inhibitors for sustained drug delivery
发明人：STINCHCOMB AUDRA L; GHOSH PRIYANKA
权利人:STINCHCOMB AUDRA L; GHOSH PRIYANKA; UNIV MARYLAND; UNIV KENTUCKY RES FOUND
摘要:Microneedles and their use as a physical skin permeation enhancement technique facilitate drug delivery across the skin in therapeutically relevant concentrations. Micropores created in the skin by MNs reseal because of normal healing processes of the skin, thus limiting the duration of the drug delivery window. Pore lifetime enhancement strategies can increase effectiveness of MNs as a drug delivery mechanism by prolonging the delivery window. Fluvastatin (FLU) was used to enhance pore lifetime by inhibiting the synthesis of cholesterol, a major component of the stratum corneum lipids. The skin recovered within a 30-45-min time period following the removal of occlusion, and there was no significant irritation observed due to the treatment compared to the control sites. Thus, it can be concluded that localized skin treatment with FLU can be used to extend micropore lifetime and deliver drugs for up to 7 days across MN-treated skin.

专利号:US-9751877-B2
优先权日:2012-09-21
标题 :Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders
发明人：PETTERSSON MARTIN YOUNGJIN; JOHNSON DOUGLAS SCOTT; SUBRAMANYAM CHAKRAPANI; O'DONNELL CHRISTOPHER JOHN; AM ENDE CHRISTOPHER WILLIAM; GREEN MICHAEL ERIC; PATEL NANDINI CHATURBHAI; STIFF CORY MICHAEL; TRAN TUAN PHONG; KAUFFMAN GREGORY WAYNE; STEPAN ANTONIA FRIEDERIKE; VERHOEST PATRICK ROBERT
权利人:PFIZER
摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

专利号:US-5677346-A
优先权日:1995-01-31
标 题:Treating urinary incontinence using (S)-desethyloxybutynin
发明人：ABERG GUNNAR; MCCULLOUGH JOHN R; FANG YUE
权利人:SEPRACOR INC
摘要:A method for treating urinary incontinence while avoiding concomitant liability of adverse effects associated with racemic oxybutynin is disclosed. The method comprises administering a therapeutically effective amount of (S)-oxybutynin, (S)-desethyloxybutynin or a pharmaceutically acceptable salt thereof, substantially free of the corresponding R enantiomer. Pharmaceutical compositions in the form of tablets and transdermal devices comprising (S)-oxybutynin or (S)-desethyloxybutynin and an acceptable carrier are also disclosed, as is a synthesis of desethyloxybutynin.

专利号:US-2004192962-A1
优先权日:2003-03-28
标 题 :Process for the synthesis of enantiomerically pure cyclohexylphenyl glycolic acid

专利号:US-7993390-B2
优先权日:2002-02-08
标 题:Implantable or insertable medical device resistant to microbial growth and biofilm formation
发明人：MILLER KATHLEEN M; BUCAY-COUTO WEENNA; LI JIANMIN
权利人:BOSTON SCIENT SCIMED INC
摘要:Disclosed are implantable or insertable medical devices that provide resistance to microbial growth on and in the environment of the device and resistance to microbial adhesion and biofilm formation on the device. In particular, the invention discloses implantable or insertable medical devices that comprise at least one biocompatible matrix polymer region, an antimicrobial agent for providing resistance to microbial growth and/or a microbial adhesion/biofilm synthesis inhibitor for inhibiting the attachment of microbes and the synthesis and accumulation of biofilm on the surface of the medical device. Also disclosed are methods of manufacturing such devices under conditions that substantially prevent preferential partitioning of any of said bioactive agents to a surface of the biocompatible matrix polymer and substantially prevent chemical modification of said bioactive agents.